Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
- PMID: 32224379
- DOI: 10.1016/j.ejmech.2020.112260
Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview
Erratum in
-
Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].Eur J Med Chem. 2020 Nov 1;205:112642. doi: 10.1016/j.ejmech.2020.112642. Epub 2020 Aug 1. Eur J Med Chem. 2020. PMID: 32750565 No abstract available.
Abstract
Matrix metalloproteinases (MMPs) are zinc dependent proteolytic metalloenzyme. MMP-9 is one of the most complex forms of matrix metalloproteinases. MMP-9 has the ability to degrade the extracellular matrix (ECM) components and has important role in the pathophysiological functions. Overexpression and dysregulation of MMP-9 is associated with various diseases. Thus, regulation and inhibition of MMP-9 is an important therapeutic approach for combating various diseases including cancer. Inhibitors of MMP-9 can be used as anticancer agents. Till date no selective MMP-9 inhibitors passed the clinical trials. In this review the structure, activation, function and inhibitors of MMP-9 are mainly focused. Some highly active and/or selective MMP-9 inhibitors have been discussed which may be helpful to explore the structural significance of MMP-9 inhibitors. This study may be useful to design new potent and selective MMP-9 inhibitors against cancer in future.
Keywords: Cancer; Hydroxamate; MMP-9; MMP-9 inhibitor; Matrix metalloproteinase.
Copyright © 2020 Elsevier Masson SAS. All rights reserved.
Conflict of interest statement
Declaration of interest statement The authors have no conflict of interests.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical
Miscellaneous
